Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 582

1.

The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly.

Patti G, Cavallari I, Hanon O, De Caterina R.

Int J Cardiol. 2018 Aug 15;265:118-124. doi: 10.1016/j.ijcard.2018.02.066.

PMID:
29885678
2.

Aspirin and Prognosis in Heart Failure: A Question of Power.

Aimo A, Ripoli A, De Caterina R, Emdin M.

JACC Heart Fail. 2018 Jun;6(6):538-539. doi: 10.1016/j.jchf.2018.02.009. No abstract available.

PMID:
29852936
3.

Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe.

Schnabel RB, Pecen L, Rzayeva N, Lucerna M, Purmah Y, Ojeda FM, De Caterina R, Kirchhof P.

J Am Heart Assoc. 2018 May 18;7(11). pii: e007559. doi: 10.1161/JAHA.117.007559.

4.

Grading of aortic stenosis severity: a head-to-head comparison between cardiac magnetic resonance imaging and echocardiography.

Mantini C, Di Giammarco G, Pizzicannella J, Gallina S, Ricci F, D'Ugo E, Marchetti M, Cotroneo AR, Ahmed N, Bucciarelli-Ducci C, Tartaro A, De Caterina R.

Radiol Med. 2018 May 5. doi: 10.1007/s11547-018-0895-2. [Epub ahead of print]

PMID:
29730841
5.

Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy.

Siller-Matula JM, Pecen L, Patti G, Lucerna M, Kirchhof P, Lesiak M, Huber K, Verheugt FWA, Lang IM, Renda G, Schnabel RB, Wachter R, Kotecha D, Sellal JM, Rohla M, Ricci F, De Caterina R; TEAM in AF group.

Int J Cardiol. 2018 Aug 15;265:141-147. doi: 10.1016/j.ijcard.2018.04.093. Epub 2018 Apr 22.

PMID:
29706429
6.

Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis.

Radico F, Zimarino M, Fulgenzi F, Ricci F, Di Nicola M, Jespersen L, Chang SM, Humphries KH, Marzilli M, De Caterina R.

Eur Heart J. 2018 Jun 14;39(23):2135-2146. doi: 10.1093/eurheartj/ehy185.

PMID:
29688324
7.

Innate and adaptive immunity in atherosclerosis.

Miteva K, Madonna R, De Caterina R, Van Linthout S.

Vascul Pharmacol. 2018 Apr 22. pii: S1537-1891(17)30464-0. doi: 10.1016/j.vph.2018.04.006. [Epub ahead of print] Review.

PMID:
29684642
8.

Scoring atherosclerosis in the search of evidence-based personalized medicine.

Ricci F, De Caterina R, Zimarino M.

Int J Cardiol. 2018 Jun 15;261:30-31. doi: 10.1016/j.ijcard.2018.03.038. No abstract available.

PMID:
29657051
9.

State of play and future direction with NOACs: An expert consensus.

Cohen AT, Lip GY, De Caterina R, Heidbuchel H, Zamorano JL, Agnelli G, Verheugt F, Camm AJ.

Vascul Pharmacol. 2018 Jul;106:9-21. doi: 10.1016/j.vph.2018.04.001. Epub 2018 Apr 12. Review.

PMID:
29656119
10.

Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes.

B Schnabel R, Pecen L, Engler D, Lucerna M, Sellal JM, Ojeda FM, De Caterina R, Kirchhof P.

Heart. 2018 Mar 17. pii: heartjnl-2017-312569. doi: 10.1136/heartjnl-2017-312569. [Epub ahead of print]

PMID:
29550771
11.

Coronary computed tomography angiography, ECG stress test and nuclear imaging as sources of false-positive results in the detection of coronary artery disease.

Zimarino M, Marano R, Radico F, Curione D, De Caterina R.

J Cardiovasc Med (Hagerstown). 2018 Feb;19 Suppl 1:e133-e138. doi: 10.2459/JCM.0000000000000591. No abstract available.

PMID:
29538163
12.

Oral anticoagulants for atrial fibrillation and acute coronary syndrome with or without stenting.

Muscente F, Tautermann G, De Caterina R.

J Cardiovasc Med (Hagerstown). 2018 Feb;19 Suppl 1:e40-e45. doi: 10.2459/JCM.0000000000000597. No abstract available.

PMID:
29538143
13.

Digoxin and Mortality in Patients With Atrial Fibrillation.

Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, Ridefelt P, Lawrence JH, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser SH, Alexander JH, Granger CB, Wallentin L; ARISTOTLE Committees and Investigators.

J Am Coll Cardiol. 2018 Mar 13;71(10):1063-1074. doi: 10.1016/j.jacc.2017.12.060.

PMID:
29519345
14.

[Diagnosis and treatment of blood volume changes in acute heart failure - a brief practical guide].

Ciancetta P, M Maggiore S, Petrini F, De Caterina R.

G Ital Cardiol (Rome). 2018 Jan;19(1):44-53. doi: 10.1714/2852.28778. Italian.

PMID:
29451509
15.

Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage.

Madonna R, Pieragostino D, Balistreri CR, Rossi C, Geng YJ, Del Boccio P, De Caterina R.

Vascul Pharmacol. 2018 Feb 6. pii: S1537-1891(17)30322-1. doi: 10.1016/j.vph.2018.01.009. [Epub ahead of print] Review.

PMID:
29425894
16.

Percutaneous coronary interventions for non-ST elevation acute coronary syndromes - The two faces of inappropriateness.

De Caterina R, Marzilli M.

Int J Cardiol. 2018 Mar 15;255:20-21. doi: 10.1016/j.ijcard.2018.01.016. No abstract available.

PMID:
29425559
17.

Proceedings of the 11th Congress of the International Society of Nutrigenetics and Nutrigenomics (ISNN 2017).

Barrington WT, Salvador AC, Hartiala JA, De Caterina R, Kohlmeier M, Martinez JA, Kreutzer CB, Heber D, Lusis AJ, Li Z, Allayee H.

J Nutrigenet Nutrigenomics. 2017;10(5-6):155-162. doi: 10.1159/000485799. Epub 2018 Jan 17.

18.

Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review.

Mundi S, Massaro M, Scoditti E, Carluccio MA, van Hinsbergh VWM, Iruela-Arispe ML, De Caterina R.

Cardiovasc Res. 2018 Jan 1;114(1):35-52. doi: 10.1093/cvr/cvx226.

PMID:
29228169
20.

Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).

Lip GYH, Merino JL, Dan GA, Themistoclakis S, Ellenbogen KA, De Caterina R, Goudev A, Jin J, Melino M, Winters SM, Goette A.

Am J Cardiol. 2018 Jan 15;121(2):193-198. doi: 10.1016/j.amjcard.2017.10.008. Epub 2017 Nov 20.

21.

Prognostic value of pulmonary blood volume by first-pass contrast-enhanced CMR in heart failure outpatients: the PROVE-HF study.

Ricci F, Barison A, Todiere G, Mantini C, Cotroneo AR, Emdin M, De Caterina R, Galllina S, Aquaro GD.

Eur Heart J Cardiovasc Imaging. 2017 Oct 17. doi: 10.1093/ehjci/jex214. [Epub ahead of print]

PMID:
29045598
22.

Aspirin and the prevention of a common disease: Colorectal cancer.

Andreotti F, De Caterina R, Crea F.

Int J Cardiol. 2017 Dec 1;248:394-395. doi: 10.1016/j.ijcard.2017.08.013. No abstract available.

PMID:
28942879
23.

Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.

De Caterina R, Brüggenjürgen B, Darius H, Köhler S, Lucerna M, Pecen L, Renda G, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P.

Arch Cardiovasc Dis. 2018 Feb;111(2):74-84. doi: 10.1016/j.acvd.2017.04.007. Epub 2017 Sep 21.

PMID:
28942115
24.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group.

N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.

25.

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators.

N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27.

26.
27.

Interindividual Variability in Biomarkers of Cardiometabolic Health after Consumption of Major Plant-Food Bioactive Compounds and the Determinants Involved.

Milenkovic D, Morand C, Cassidy A, Konic-Ristic A, Tomás-Barberán F, Ordovas JM, Kroon P, De Caterina R, Rodriguez-Mateos A.

Adv Nutr. 2017 Jul 14;8(4):558-570. doi: 10.3945/an.116.013623. Print 2017 Jul. Review.

PMID:
28710143
28.

Guide for Current Nutrigenetic, Nutrigenomic, and Nutriepigenetic Approaches for Precision Nutrition Involving the Prevention and Management of Chronic Diseases Associated with Obesity.

Ramos-Lopez O, Milagro FI, Allayee H, Chmurzynska A, Choi MS, Curi R, De Caterina R, Ferguson LR, Goni L, Kang JX, Kohlmeier M, Marti A, Moreno LA, Pérusse L, Prasad C, Qi L, Reifen R, Riezu-Boj JI, San-Cristobal R, Santos JL, Martínez JA.

J Nutrigenet Nutrigenomics. 2017;10(1-2):43-62. doi: 10.1159/000477729. Epub 2017 Jul 8.

29.

Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study.

Briguori C, Quintavalle C, D'Alessio F, Donahue M, Roscigno G, De Micco F, Focaccio A, Visconti G, Del Vecchio L, Madonna R, De Caterina R, Condorelli G.

Int J Cardiol. 2017 Oct 1;244:112-118. doi: 10.1016/j.ijcard.2017.06.087. Epub 2017 Jun 27.

PMID:
28668399
30.

Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making.

Lip G, Freedman B, De Caterina R, Potpara TS.

Thromb Haemost. 2017 Jun 28;117(7):1230-1239. doi: 10.1160/TH16-11-0876. Epub 2017 Jun 9. Review.

PMID:
28597905
31.

Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.

Volpe M, Battistoni A, Gallo G, Coluccia R, De Caterina R.

High Blood Press Cardiovasc Prev. 2017 Sep;24(3):331-339. doi: 10.1007/s40292-017-0213-4. Epub 2017 Jun 1. Review.

PMID:
28573479
32.

Aspirin in heart failure: don't throw the baby (aspirin) out with the bathwater.

De Caterina R.

Eur J Heart Fail. 2017 Sep;19(9):1089-1094. doi: 10.1002/ejhf.894. Epub 2017 May 31. No abstract available.

PMID:
28560745
33.

[Cardiac tumors: role of magnetic resonance imaging].

Bianco F, Bucciarelli V, Todiere G, Barison A, Festa P, Ait-Ali L, Gallina S, De Caterina R, Aquaro GD.

G Ital Cardiol (Rome). 2017 Apr;18(4):286-294. doi: 10.1714/2683.27471. Review. Italian.

PMID:
28492568
34.

[Biomarkers in primary cardiovascular prevention: rationale, premises, and promises].

Muscente F, De Caterina R.

G Ital Cardiol (Rome). 2017 Feb;18(2):106-120. doi: 10.1714/2663.27296. Review. Italian.

PMID:
28398364
35.

The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.

De Caterina R, Lip GYH.

Clin Res Cardiol. 2017 Aug;106(8):565-572. doi: 10.1007/s00392-017-1102-5. Epub 2017 Apr 10. Review.

PMID:
28396988
36.

The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy.

Madonna R, Renna FV, Lanuti P, Perfetti M, Marchisio M, Briguori C, Condorelli G, Manzoli L, De Caterina R.

PLoS One. 2017 Apr 10;12(4):e0172800. doi: 10.1371/journal.pone.0172800. eCollection 2017.

37.

Lung ultrasonography: a practical guide for cardiologists.

Bianco F, Bucciarelli V, Ricci F, De Caterina R, Gallina S.

J Cardiovasc Med (Hagerstown). 2017 Jul;18(7):501-509. doi: 10.2459/JCM.0000000000000515. Review.

PMID:
28306695
38.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

39.

Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.

De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff CT, Antman EM, Braunwald E, Giugliano RP.

J Am Coll Cardiol. 2017 Mar 21;69(11):1372-1382. doi: 10.1016/j.jacc.2016.12.031.

40.

Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.

Renda G, Ricci F, Giugliano RP, De Caterina R.

J Am Coll Cardiol. 2017 Mar 21;69(11):1363-1371. doi: 10.1016/j.jacc.2016.12.038.

41.

[Aspirin for primary cardiovascular disease prevention - an update].

De Caterina R.

G Ital Cardiol (Rome). 2017 Jan;18(1):1-6. doi: 10.1714/2628.27020. Italian. No abstract available.

PMID:
28287208
42.

Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.

Westenbrink BD, Alings M, Granger CB, Alexander JH, Lopes RD, Hylek EM, Thomas L, Wojdyla DM, Hanna M, Keltai M, Steg PG, De Caterina R, Wallentin L, van Gilst WH.

Am Heart J. 2017 Mar;185:140-149. doi: 10.1016/j.ahj.2016.12.008. Epub 2016 Dec 22.

43.

Right heart-pulmonary circulation unit and cardiac resynchronization therapy.

Ricci F, Mele D, Bianco F, Bucciarelli V, De Caterina R, Gallina S.

Am Heart J. 2017 Mar;185:1-16. doi: 10.1016/j.ahj.2016.11.005. Epub 2016 Nov 17. Review.

PMID:
28267462
44.

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.

Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman E, Giugliano RP; ENGAGE AF-TIMI 48 Investigators.

Circulation. 2017 Mar 28;135(13):1273-1275. doi: 10.1161/CIRCULATIONAHA.116.026714. Epub 2017 Feb 16. No abstract available.

45.

Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.

Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP, Siller-Matula JM.

Eur Heart J Cardiovasc Pharmacother. 2017 Oct 1;3(4):221-234. doi: 10.1093/ehjcvp/pvw044.

PMID:
28204303
46.

Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.

De Caterina R, Ageno W, Boriani G, Colonna P, Ghirarduzzi A, Patti G, Rossini R, Rubboli A, Schinco P, Agnelli G.

Adv Ther. 2017 Mar;34(3):620-637. doi: 10.1007/s12325-017-0488-9. Epub 2017 Feb 13. Review.

47.

ESC working group position paper on myocardial infarction with non-obstructive coronary arteries.

Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, De Caterina R, Zimarino M, Roffi M, Kjeldsen K, Atar D, Kaski JC, Sechtem U, Tornvall P; WG on Cardiovascular Pharmacotherapy.

Eur Heart J. 2017 Jan 14;38(3):143-153. doi: 10.1093/eurheartj/ehw149. No abstract available.

PMID:
28158518
48.

[Management of acute coronary syndromes in the Abruzzi Region in Italy. Abruzzi Inter-societary Consensus Document.]

Mascellanti M, Zimarino M, De Caterina R.

Recenti Prog Med. 2017 Jan;108(1):52-59. doi: 10.1701/2624.26983. Italian.

PMID:
28151527
49.

[Contrast-induced acute kidney injury in cardiology].

Genovesi E, Romanello M, De Caterina R.

G Ital Cardiol (Rome). 2016 Dec;17(12):984-1000. doi: 10.1714/2612.26891. Review. Italian.

PMID:
28151503
50.

Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches.

Madonna R, Balistreri CR, Geng YJ, De Caterina R.

Vascul Pharmacol. 2017 Mar;90:1-7. doi: 10.1016/j.vph.2017.01.004. Epub 2017 Jan 28. Review.

PMID:
28137665

Supplemental Content

Loading ...
Support Center